“4 Stocks to Buy Before the End of 2026!”
AI summary · KRYS is a great, profitable, early-growth biotech: marketed Vyjuvek is highly profitable, Q3 revenue was $127 million, up 30% year over year, with 94% gross margin, over $1 billion cumulative revenue and $1.2 billion cash; it is expanding into other rare diseases and internationally and approved a $400 million buyback over two years. A 10%+ post-earnings drop reflected two clinical readouts delayed to 2027, which the speaker says is not worrisome; the stock is at least a watchlist, if not buy-list, name for biotech investors.
Moving on to a completely different sector, we should talk about healthcare. I'm going to talk about Crystal Biotech, and the code is K R Y S.
So, Crystal Biotech, if you're not familiar with it, is a bit of an unknown in the world of emerging biotech companies. This is a company in the commercial phase. They already have a proven and highly profitable product.
So, this is not a bet on the results of a future clinical trial.